- Report
- April 2025
- 185 Pages
Global
From €4105EUR$4,500USD£3,509GBP
- Report
- April 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- March 2025
- 187 Pages
Global
From €3234EUR$3,545USD£2,764GBP
€3593EUR$3,939USD£3,071GBP
- Report
- April 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- April 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- February 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- February 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- April 2023
- 175 Pages
Global
From €5381EUR$5,899USD£4,600GBP
- Report
- January 2024
- 269 Pages
Global
From €6637EUR$7,530USD£5,481GBP
- Report
- August 2024
- 96 Pages
Global
From €3500EUR$4,110USD£3,096GBP
- Report
- February 2024
- 75 Pages
Global
From €3500EUR$4,110USD£3,096GBP
- Report
- October 2023
- 306 Pages
Global
From €2280EUR$2,499USD£1,949GBP
€3257EUR$3,570USD£2,784GBP
Clarithromycin is an antibiotic used to treat a variety of bacterial infections. It belongs to a class of antibiotics known as macrolides, which work by inhibiting the growth of bacteria. Clarithromycin is commonly used to treat respiratory tract infections, skin infections, and sexually transmitted diseases. It is also used to prevent certain types of bacterial infections in people with weakened immune systems. Clarithromycin is available in both oral and intravenous forms.
The Clarithromycin market is highly competitive, with a number of companies offering the drug. Major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and AstraZeneca. Other companies in the market include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
